(IN BRIEF) Sanofi has received FDA priority review for the new drug application for venglustat, an investigational oral glucosylceramide synthase inhibitor being developed for type 3 Gaucher disease. The FDA’s target action date is 25 November 2026. If approved, venglustat … Read the full press release
Posted in European Union, France, Healthcare, Marketing, Pharma & Biotech
Tagged adult patients, ataxia, biopharma, blood-brain barrier, breakthrough therapy designation, central nervous system, cerebrospinal fluid, cognitive deficits, enzyme replacement therapy, ERT, EURONEXT: SAN, Fabry disease, Fast Track Designation, FDA, Gaucher disease, GCSi, GD3, GL1, glucosylceramide synthase inhibitor, glycosphingolipids, GSL, haemoglobin, LEAP2MONO, liver volume, lyso-GL1, lysosomal storage disease treatments, lysosomal storage disorder, Nasdaq SNY, NCT05222906, NDA, neuroinflammation, neurological manifestations, New Drug Application, orphan designation, paediatric patients, Paris, phase 3 study, platelet count, Priority Review, rare diseases, Sanofi, Sanofi Builds Rare Disease Pipeline as FDA Accepts Venglustat Application for Priority Review in GD3, Sanofi’s Venglustat Could Become First U.S. Treatment Targeting Neurological Symptoms of Type 3 Gaucher Disease, Sanofi’s Venglustat Receives FDA Priority Review for Potential Treatment of Type 3 Gaucher Disease, Sanofi’s Venglustat Receives FDA Priority Review for Type 3 Gaucher Disease Treatment in the United States, spleen volume, type 3 Gaucher disease, U.S. Food and Drug Administration, venglustat, WORLDSymposium
MUNICH, 09-Jan-2018 — /EuropaWire/ — Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system, in which the body’s own immune cells attack the fatty, insulating myelin sheath surrounding nerve fibers. The regeneration of intact myelin … Read the full press release
GENEVA, 08-Jun-2016 — /EuropaWire/ — TESTmyBRAIN (Switzerland) has opened its first center of Functional Neurology in Europe. This non-invasive therapy (no medication, no surgery) coming from the United States helps patients suffering from migraines, concussions, strokes, AD/HD, Parkinson disease, Alzheimer, … Read the full press release
Posted in Education, Germany, Healthcare, Netherlands, News, Sports, Switzerland, United Kingdom
Tagged ADHD, Alzheimer, central nervous system, Concussions, dizziness, headaches, migraines, Mr. Claude Martinet, Parkinson, stroke, Switzerland, TESTmyBRAIN, testmybrain.ch
Cordoba, Spain, 12-6-2013 — /europawire.eu/ — VivaCell Biotechnology España S.L., Cordoba, Spain today announced that it has entered into joint Research Collaboration and Commercialization Agreements with Aphios Corporation, USA, to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Aphios Corporation, biotech company, biotech development, biotech pharma companies, biotechnology, cannabinoid receptor, cannabinoids, central nervous system, CNS and neurological disorders, Cordoba, endocannabinoid system, multiple sclerosis, neurodegenerative diseases, novel class of compounds, therapeutics for multiple sclerosis, VivaCell Biotechnology, VivaCell Biotechnology España S.L.
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?